Lilly says US demand for its Foundayo pill more than tripled last quarter
Lilly's oral obesity pill Foundayo made $184m in Q3, short of analyst forecasts, but Lilly says underlying US demand rose from about $37m to over $120m once launch stock-filling is stripped out. IQVIA counted about 63,000 weekly US scripts in late October, still roughly a third of the Wegovy pill's. Foundayo is now sold in four countries including the UK.
Image credit: Chosunbiz
Source: Chosunbiz (2 Nov 2026). Image: Chosunbiz.